

# Andreas Stahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6230317/publications.pdf>

Version: 2024-02-01

29  
papers

1,435  
citations

516215

16  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1329  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Classification of Retinopathy of Prematurity, Third Edition. <i>Ophthalmology</i> , 2021, 128, e51-e68.	2.5	280
2	Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1551-1559.	6.3	268
3	Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. <i>British Journal of Ophthalmology</i> , 2017, 101, bjophthalmol-2016-308668.	2.1	120
4	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity. <i>JAMA Pediatrics</i> , 2018, 172, 278.	3.3	111
5	Bevacizumab in retinal vein occlusion-results of a prospective case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1429-1436.	1.0	109
6	Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 13-20.	0.9	101
7	Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2151-2157.	1.0	53
8	Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics. <i>JAMA Ophthalmology</i> , 2020, 138, 21.	1.4	41
9	OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis. <i>Ophthalmology and Therapy</i> , 2019, 8, 75-86.	1.0	40
10	Transcriptomic Characterization of Human Choroidal Neovascular Membranes Identifies Calprotectin as a Novel Biomarker for Patients with Age-Related Macular Degeneration. <i>American Journal of Pathology</i> , 2020, 190, 1632-1642.	1.9	38
11	The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. <i>Acta Ophthalmologica</i> , 2016, 94, e744-e752.	0.6	31
12	Transcriptional Profiling Uncovers Human Hyalocytes as a Unique Innate Immune Cell Population. <i>Frontiers in Immunology</i> , 2020, 11, 567274.	2.2	27
13	Artificial Intelligence for Retinopathy of Prematurity. <i>Ophthalmology</i> , 2022, 129, e69-e76.	2.5	23
14	Sema3f Protects Against Subretinal Neovascularization In Vivo. <i>EBioMedicine</i> , 2017, 18, 281-287.	2.7	20
15	Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. <i>Acta Ophthalmologica</i> , 2020, 98, e530.	0.6	19
16	Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	18
17	CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy. , 2016, 57, 4017.		17
18	Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. <i>Ophthalmology Retina</i> , 2022, 6, 628-637.	1.2	16

#	ARTICLE	IF	CITATIONS
19	Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. <i>JAMA Ophthalmology</i> , 2019, 137, 305.	1.4	15
20	Semaphorin 3F Modulates Corneal Lymphangiogenesis and Promotes Corneal Graft Survival. , 2018, 59, 5277.		13
21	Screening and Treatment in Retinopathy of Prematurity. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2015, 112, 730-5.	0.6	12
22	SHIP-MR and Radiology: 12 Years of Whole-Body Magnetic Resonance Imaging in a Single Center. <i>Healthcare (Switzerland)</i> , 2022, 10, 33.	1.0	11
23	Acute unilateral maculopathy associated with adult onset of hand, foot and mouth disease: a case report. <i>BMC Ophthalmology</i> , 2019, 19, 104.	0.6	8
24	Anti-€drug antibodies to brolocizumab and ranibizumab in serum and vitreous of patients with ocular disease. <i>Acta Ophthalmologica</i> , 2022, 100, 903-910.	0.6	8
25	Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. <i>British Journal of Ophthalmology</i> , 2022, 106, 1573-1580.	2.1	6
26	Systemic confounders affecting serum measurements of omega-3 and -6 polyunsaturated fatty acids in patients with retinal disease. <i>BMC Ophthalmology</i> , 2016, 16, 159.	0.6	5
27	Validation of the Retinopathy of Prematurity Activity Scale (ROP-€ActS) using retrospective clinical data. <i>Acta Ophthalmologica</i> , 2021, 99, 201-206.	0.6	5
28	Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1565-1571.	1.0	4
29	Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy -€ The non-€interventional second year follow-€up to the PRIDE study. <i>Acta Ophthalmologica</i> , 2021, , .	0.6	4